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One of the fundamental advantages of xenotrans-
plantation is that the donor organ, because it is
derived from a pig, can be genetically modified to
relieve the patient of as much of the immuno-
suppressive burden as possible. The first example
of the utility of this approach was the develop-
ment of human complement regulatory protein
pigs which essentially eliminated hyperacute rejec-
tion (HAR) and extended cardiac xenograft
survival from less than a few hours to 5–7 days.
These donor organs eliminated the need for
systemic complement inhibition and thereby sig-
nificantly reduced the immunosuppressive burden
of the recipient. With the advent of nuclear
transfer technology, and the extension of that
technique to agricultural species, it became poss-
ible to produce pigs with targeted mutations. This
lead to the disruption of the porcine a-galacto-
syltransferase gene which catalyzes the terminal
addition of UDP-galactose to produce the a-Gal
carbohydrate. As optimal control of a-Gal anti-
bodies using daily infusions of Gal-polymers had
resulted in median cardiac xenograft survival
beyond 3 months, the creation of pigs deficient
in the a-Gal antigen was widely anticipated to
eliminate the need for a-Gal polymers and per-
haps extend graft survival by reducing the inten-
sity of the overall immune response. Before the
utility of gene-knockout (GT-KO) donors for
clinical xenotransplantation can be determined,
there are three major questions that should be
addressed: First, will these animals be phenotyp-
ically normal and will they reproduce through
natural breeding? Secondly, will using GT-KO pig
hearts eliminate the need for infusion of a-Gal
polymers and achieve similar survival times?
Finally, what form of rejection will be observed
using GT-KO organs and how will this new
hurdle be overcome?
The Mayo group, in collaboration with Nex-
tran, developed GT-KO pigs from porcine fetal
fibroblasts containing a neomycin insertion that
disrupts exon 9 of the a-galactosyltransferase
gene [1]. The initial heterozygous female animals
were bred to a series of unrelated male pigs
carrying an hDAF transgene and the offspring
were backcrossed to produce homozygous GT-
KO and GT-KO; hDAF pigs. We presented the
lineage of GT heterozygous by heterozygous and
GT-KO homozygous boar by heterozygous sow
matings. All of the GT-KO animals produced to
date were healthy and showed no evidence of
cataracts, a phenotype initially reported in GT-
KO mice. Production of the GT-KO genotype
has been at or near the predicted Mendelian
frequencies.
We also reported on a series of eight GT-KO
pig to baboon heterotopic heart transplants that
used a maintenance immunosuppressive regimen
that matched a previous study using GT+ CD46
transplants in which the recipients were success-
fully treated with daily infusion of a-Gal poly-
mers to block anti-Gal function and induction.
These GT-KO transplants were designed to test
the efficacy of GT-KO donor hearts as a
substitute for a-Gal polymers. The recipients
were not pre-selected for low levels of preformed
non-Gal antibody as this form of selection was
not possible in previous transplants. Unexpect-
edly, one of these hearts underwent HAR. While
immediate graft function after reperfusion was
excellent, within 10 min the graft exhibited dis-
coloration which progressed globally until graft
failure 90 min after reperfusion. Flow cytometry
using GT-KO porcine aortic endothelial cells
confirmed the presence of preformed non-Gal
IgM and IgG and the cytolytic nature of this
preformed antibody in the recipient. Histological
analysis of the graft showed typical HAR inclu-
ding widespread edema and hemorrhage with
strong vascular deposition of IgM and C5b. The
remaining transplants survived for a median of
27 days (range: 2–128 days) with five out of
seven grafts exhibiting graft failure and delayed
xenograft rejection. All grafts had vascular anti-
body deposition at the time of explant with
variable levels of complement deposition. Survi-
val of these GT-KO organs was comparable with
the survival of GT+ CD46 transgenic hearts in
recipients treated with an a-Gal polymer to
control induction of anti-Gal antibody.
We believe that the GT-KO donors may be
clinically useful as they may eliminate the need
for intravenous a-Gal polymers, however, the
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HAR of one graft and the uniform presence of
vascular antibody in the remaining transplants
illustrate the pathogenic potential of preformed
non-Gal anti-pig antibody and suggest that non-
Gal antibody response will dominate contempor-
ary xenograft rejection.
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Current status of pig-to-non-human primate
organ transplantation
Recent studies using organs from a1,3-galacto-
syltransferase gene-knockout (GT-KO) pigs [1–3]
transplanted into non-human primates have indi-
cated that, if the immunosuppressive regimen
prevents a T cell-dependent elicited antibody
response, the organs survive for several weeks
or months before graft failure [4–6]. In partic-
ular, heterotopic hearts transplanted into ba-
boons functioned from 2 to 6 months before
succumbing to a thrombotic microangiopathy
(TM) [4,5], the histology of which is quite
different from the acute humoral xenograft
rejection seen previously [7]. TM had been seen
previously in hearts from pigs transgenic for
human decay-accelerating factor (hDAF) [8],
using the same immunosuppressive regimen, but
with an additional continuous intravenous infu-
sion of a Gala1,3Gal (Gal)-conjugate to adsorb
and deplete anti-Gal antibodies [9].
Although the survival of the GT-KO hearts
was not greatly extended when compared with
the hDAF hearts, the lack of necessity of
administering a Gal-conjugate represents a signi-
ficant advance. Clearly, the less suppression of
the host immune system that is required, then the
fewer will be the complications of the regimen. In
the eight experiments performed in which a GT-
KO heart was transplanted into a baboon, there
were no infectious complications, and no other
complications directly attributable to the immu-
nosuppressive regimen. This indicates that this
regimen would be tolerated in humans, even
though the anti-CD154 monoclonal antibody
(mAb) that is an integral part of the regimen is
unlikely to be used clinically because of its
known association with thrombotic events [10].
In this respect, the TM seen in the transplanted
organs was not thought to be associated with the
administration of this agent because: (i) TM was
not seen in any of the native organs, and (ii) TM
has also been reported by others who used a
regimen based on conventional pharmacologic
immunosuppressive therapy [11,12].
Potential factors contributing to thrombotic
microangiopathy
The binding of natural anti-non-Gal antibodies
to the vascular endothelial cells of the graft
might activate those cells and/or initiate injury
that may lead to a local change from an anti-
coagulant to a procoagulant state. In this regard,
we have documented that humans [13], baboons
[14], and monkeys [15] produce anti-non-Gal
cytotoxic antibodies, and these contribute
approximately 50% of the natural anti-pig anti-
bodies in these species. It has also been docu-
mented that, if immunosuppression is not
adequate, there is a significant elicited anti-non-
Gal antibody response after GT-KO pig organ
transplantation [14,16]. However, evidence, lar-
gely from rodent studies [17–19], suggests that
coagulation dysregulation may also play a signi-
ficant role in the development of TM, possibly
secondary to endothelial cell activation from
binding of anti-non-Gal antibodies.
Potential solutions
Potential solutions involve identification of the
specific antigens to which anti-non-Gal antibodies
bind [20,21], which would allow the knockout of
the gene(s) responsible for the expression of the
antigen(s). However, there may be multiple non-
Gal antigens involved, and the knockout approach
may be difficult and/or time-consuming. An alter-
native would be to genetically engineer the GT-KO
pig to express high levels of a human complement-
regulatory protein, such as hDAF, or increased
expression of a pig complement-regulatory protein,
to protect the vascular endothelium from comple-
ment-mediated injury initiated by the binding of
anti-non-Gal antibodies. An equally successful
approach may be to genetically engineer the pig
to express a human ‘anti-coagulant’ gene, such as
tissue factor pathway inhibitor, thrombomodulin
or CD39.
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